Tenaya Therapeutics (TNYA)
(Delayed Data from NSDQ)
$3.51 USD
+0.01 (0.29%)
Updated Jul 12, 2024 04:00 PM ET
After-Market: $3.50 -0.01 (-0.28%) 7:58 PM ET
3-Hold of 5 3
F Value C Growth C Momentum F VGM
Income Statements
Fiscal Year end for Tenaya Therapeutics, Inc falls in the month of December .
All items in Millions except EPS data.
12/31/23 | 12/31/22 | 12/31/21 | 12/31/20 | 12/31/19 | |
---|---|---|---|---|---|
Sales | 0 | 0 | 0 | 0 | 0 |
Cost Of Goods | 0 | 0 | 0 | 0 | 0 |
Gross Profit | 0 | 0 | 0 | 0 | 0 |
Selling & Adminstrative & Depr. & Amort Expenses | 131 | 126 | 73 | 39 | 0 |
Income After Depreciation & Amortization | -131 | -126 | -73 | -39 | 0 |
Non-Operating Income | 7 | 2 | 0 | 1 | 0 |
Interest Expense | 0 | 0 | 0 | 0 | 0 |
Pretax Income | -124 | -124 | -73 | -38 | 0 |
Income Taxes | 0 | 0 | 0 | 0 | 0 |
Minority Interest | 0 | 0 | 0 | 0 | 0 |
Investment Gains/Losses | 0 | 0 | 0 | 0 | 0 |
Other Income/Charges | 0 | 0 | 0 | 0 | 0 |
Income From Cont. Operations | -124 | -124 | -73 | -38 | 0 |
Extras & Discontinued Operations | 0 | 0 | 0 | 0 | 0 |
Net Income (GAAP) | -124 | -124 | -73 | -38 | 0 |
Depreciation Footnote | 12/31/23 | 12/31/22 | 12/31/21 | 12/31/20 | 12/31/19 |
---|---|---|---|---|---|
Income Before Depreciation & Amortization | -122 | -119 | -70 | -36 | 0 |
Depreciation & Amortization (Cash Flow) | 9 | 6 | 3 | 2 | 0 |
Income After Depreciation & Amortization | -131 | -126 | -73 | -39 | 0 |
Earnings Per Share Data | 12/31/23 | 12/31/22 | 12/31/21 | 12/31/20 | 12/31/19 |
---|---|---|---|---|---|
Average Shares | 73.79 | 44.82 | 17.73 | NA | NA |
Diluted EPS Before Non-Recurring Items | -1.68 | -2.76 | -4.10 | NA | NA |
Diluted Net EPS (GAAP) | -1.68 | -2.76 | -4.10 | -39.50 | NA |
Fiscal Year end for Tenaya Therapeutics, Inc falls in the month of December .
All items in Millions except EPS data.
6/30/24 | 3/31/24 | 12/31/23 | 9/30/23 | 6/30/23 | |
---|---|---|---|---|---|
Sales | NA | 0.00 | 0.00 | 0.00 | 0.00 |
Cost Of Goods | NA | 0.00 | 0.00 | 0.00 | 0.00 |
Gross Profit | NA | 0.00 | 0.00 | 0.00 | 0.00 |
SG&A, R&D, and Dept/Amort Expenses | 0.00 | 33.77 | 31.45 | 30.92 | 35.11 |
Income After SG&A, R&D, and Dept/Amort Expenses | 0.00 | -33.77 | -31.45 | -30.92 | -35.11 |
Non-Operating Income | NA | 1.53 | 1.51 | 1.78 | 1.84 |
Interest Expense | NA | 0.00 | 0.00 | 0.00 | 0.00 |
Pretax Income | NA | -32.23 | -29.94 | -29.14 | -33.27 |
Income Taxes | NA | 0.00 | 0.00 | 0.00 | 0.00 |
Minority Interest | NA | 0.00 | 0.00 | 0.00 | 0.00 |
Investment Gains/Losses | NA | 0.00 | 0.00 | 0.00 | 0.00 |
Other Income/Charges | NA | 0.00 | 0.00 | 0.00 | 0.00 |
Income From Cont. Operations | NA | -32.23 | -29.94 | -29.14 | -33.27 |
Extras & Discontinued Operations | NA | 0.00 | 0.00 | 0.00 | 0.00 |
Net Income (GAAP) | NA | -32.23 | -29.94 | -29.14 | -33.27 |
Earnings Per Share Data | 6/30/24 | 3/31/24 | 12/31/23 | 9/30/23 | 6/30/23 |
---|---|---|---|---|---|
Average Shares | NA | 80.98 | 74.10 | 73.93 | 73.40 |
Diluted EPS Before Non-Recurring Items | NA | -0.40 | -0.40 | -0.39 | -0.45 |
Diluted Net EPS (GAAP) | NA | -0.40 | -0.41 | -0.39 | -0.45 |